Castle biosciences announces publication demonstrating dermatologists are increasingly integrating decisiondx-melanoma into melanoma clinical management decisions

Friendswood, texas--(business wire)---- $cstl #decisiondxmelanoma--castle biosciences, inc. (nasdaq: cstl), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of a cross-sectional study of dermatologists that found its respondents are increasingly incorporating decisiondx®-melanoma into the management of their patients with melanoma. decisiondx-melanoma is castle's gene expression profile test that uses an individual patient's t
CSTL Ratings Summary
CSTL Quant Ranking